HCA Healthcare (HCA) EBITDA (2010 - 2026)

HCA Healthcare has disclosed EBITDA across 17 years of filings, most recently posting -$566.0 million for Q1 2026.

• In Q1 2026, EBITDA rose 62.71% year-over-year to -$566.0 million; the TTM figure through Mar 2026 stood at -$7.6 billion (down 18.79% YoY), while the FY2025 annual figure was $5.6 billion, up 9.62% from the prior year.
• EBITDA improved to -$566.0 million in Q1 2026, from -$4.8 billion in the prior quarter.
• Over the last five years, EBITDA for HCA reached as high as $2.7 billion in Q4 2022 and fell as low as -$4.8 billion in Q4 2025.
• The 5-year median for EBITDA is $1.3 billion (2022), against an average of $45.3 million.
• Annual changes were most pronounced in 2024 — EBITDA sank 345.15% — and 2026, when it jumped 62.71%.
• A 5-year view of EBITDA shows it stood at $2.7 billion in 2022, then fell by 29.88% to $1.9 billion in 2023, then slumped by 345.15% to -$4.7 billion in 2024, then declined by 2.12% to -$4.8 billion in 2025, then jumped by 88.27% to -$566.0 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$566.0 million, -$4.8 billion, and -$1.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.